Impact of Halobetasol Propionate and Tazarotene Lotion 0.01%/0.045% in the Management of Plaque Psoriasis in Adults

References

• Rachakonda TD, Schupp CW, Armstrong AW. Psoriasis prevalence among adults in the United States. J Am Acad Dermatol. 2014;70(3):512–516. doi:10.1016/j.jaad.2013.11.01324388724
   PubMed Web of Science ®Google Scholar
• Boehncke W-H, Schön MP. Psoriasis. Lancet. 2015;386(9997):983–994. doi:10.1016/S0140-6736(14)61909-726025581
   PubMed Web of Science ®Google Scholar
• Armstrong AW, Harskamp CT, Armstrong EJ. The association between psoriasis and obesity: a systematic review and meta-analysis of observational studies. Nutr Diabetes. 2012;2(12):e54–e54. doi:10.1038/nutd.2012.2623208415
   PubMed Web of Science ®Google Scholar
• Olivier C, Robert PD, Daihung D, et al. The risk of depression, anxiety, and suicidality in patients with psoriasis: a population-based cohort study. Arch Dermatol. 2010;146(8):891–895. doi:10.1001/archdermatol.2010.18620713823
   PubMedGoogle Scholar
• Takeshita J, Grewal S, Langan SM, et al. Psoriasis and comorbid diseases: epidemiology. J Am Acad Dermatol. 2017;76(3):377–390. doi:10.1016/j.jaad.2016.07.06428212759
   PubMed Web of Science ®Google Scholar
• Gelfand JM, Neimann AL, Shin DB, Wang X, Margolis DJ, Troxel AB. Risk of myocardial infarction in patients with psoriasis. JAMA. 2006;296(14):1735–1741. doi:10.1001/jama.296.14.173517032986
   PubMed Web of Science ®Google Scholar
• Armstrong AW, Harskamp CT, Armstrong EJ. The association between psoriasis and hypertension: a systematic review and meta-analysis of observational studies. J Hypertens. 2013;31(3):433–443. doi:10.1097/HJH.0b013e32835bcce123249828
   PubMed Web of Science ®Google Scholar
• Armstrong AW, Harskamp CT, Armstrong EJ. Psoriasis and the risk of diabetes mellitus: a systematic review and meta-analysis. JAMA Dermatol. 2013;149(1):84–91. doi:10.1001/2013.jamadermatol.40623407990
   PubMed Web of Science ®Google Scholar
• Schön MP, Boehncke W-H. Psoriasis. N Engl J Med. 2005;352(18):1899–1912. doi:10.1056/NEJMra04132015872205
   PubMed Web of Science ®Google Scholar
• Blum G, Yawalkar S. A comparative, multicenter, double blind trial of 0.05% halobetasol propionate ointment and 0.1 betamethasone valerate ointment in the treatment of patients with chronic, localized plaque psoriasis. J Am Acad Dermatol. 1991;25(6, Part 2):1153–1156. doi:10.1016/0190-9622(91)70315-S1757607
   PubMed Web of Science ®Google Scholar
• Goldberg B, Hartdegen R, Presbury D, Harvey Smith E, Yawalkar S. A double-blind, multicenter comparison of 0.05% halobetasol propionate ointment and 0.05% clobetasol propionate ointment in patients with chronic, localized plaque psoriasis. J Am Acad Dermatol. 1991;25(6, Part 2):1145–1148. doi:10.1016/0190-9622(91)70313-Q1757605
   PubMed Web of Science ®Google Scholar
• Mensing H, Korsukewitz G, Yawalkar S. A double-blind, multicenter comparison between 0.05% halobetasol propionate ointment and 0.05% betamethasone dipropionate ointment in chronic plaque psoriasis. J Am Acad Dermatol. 1991;25(6, Part 2):1149–1152. doi:10.1016/0190-9622(91)70314-R1757606
   PubMed Web of Science ®Google Scholar
• Weinstein GD, Koo JYM, Krueger GG, et al. Tazarotene cream in the treatment of psoriasis: two multicenter, double-blind, randomized, vehicle-controlled studies of the safety and efficacy of tazarotene creams 0.05% and 0.1% applied once daily for 12 weeks. J Am Acad Dermatol. 2003;48(5):760–767. doi:10.1067/mjd.2003.10312734506
   PubMed Web of Science ®Google Scholar
• Awad N, Preuss CV. Halobetasol Cream In: StatPearls. Treasure Island (FL): StatPearls Publishing 2020 Available from: http://www.ncbi.nlm.nih.gov/books/NBK544234/.Accessed 317, 2020.
   Google Scholar
• Kragballe K. Topical corticosteroids: mechanisms of action. Acta Derm Venereol Suppl (Stockh). 1989;151:7–10.2533778
   PubMedGoogle Scholar
• Hengge UR, Ruzicka T, Schwartz RA, Cork MJ. Adverse effects of topical glucocorticosteroids. J Am Acad Dermatol. 2006;54(1):1–15. doi:10.1016/j.jaad.2005.01.01016384751
   PubMed Web of Science ®Google Scholar
• Chandraratna R. Tazarotene—first of a new generation of receptor-selective retinoids. Br J Dermatol. 1996;135(s49):18–25. doi:10.1111/j.1365-2133.1996.tb15662.x
   PubMed Web of Science ®Google Scholar
• Retinoids in the treatment of skin aging: an overview of clinical efficacy and safety. Available from: https://www-ncbi-nlm-nih-gov.ucsf.idm.oclc.org/pmc/articles/PMC2699641/. Accessed 317, 2020.
   Google Scholar
• Heath MS, Sahni DR, Curry ZA, Feldman SR. Pharmacokinetics of tazarotene and acitretin in psoriasis. Expert Opin Drug Metab Toxicol. 2018;14(9):919–927. doi:10.1080/17425255.2018.151519830134735
   PubMed Web of Science ®Google Scholar
• Duvic M, Nagpal S, Asano AT, Chandraratna RAS. Molecular mechanisms of tazarotene action in psoriasis. J Am Acad Dermatol. 1997;37(2, Part 3):S18–S24. doi:10.1016/S0190-9622(97)80396-99270552
   PubMed Web of Science ®Google Scholar
• Lebwohl M, Poulin Y. Tazarotene in combination with topical corticosteroids. J Am Acad Dermatol. 1998;39(4, Supplement):S139–S143. doi:10.1016/S0190-9622(98)70311-19777792
   PubMed Web of Science ®Google Scholar
• DUOBRII™ Lotion [package insert]. Bridgewater, NJ: bausch Health US, LLC. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/209354s000lbl.pdf. Accessed 3 11, 2020.
   Google Scholar
• Safety and efficacy of IDP-118 in the treatment of plaque psoriasis - full text view - clinicalTrials.gov. Available from: https://clinicaltrials.gov/ct2/show/NCT02462070. Accessed 311, 2020..
   Google Scholar
• Safety and efficacy of IDP-118 in the treatment of plaque psoriasis - full text view - clinicalTrials.gov. Available from: https://clinicaltrials.gov/ct2/show/NCT02462122. Accessed 311, 2020.
   Google Scholar
• Gold LS, Lebwohl MG, Sugarman JL, et al. Safety and efficacy of a fixed combination of halobetasol and tazarotene in the treatment of moderate-to-severe plaque psoriasis: results of 2 Phase 3 randomized controlled trials. J Am Acad Dermatol. 2018;79(2):287–293. doi:10.1016/j.jaad.2018.03.04029614243
   PubMed Web of Science ®Google Scholar
• Blauvelt A, Green LJ, Lebwohl MG, et al. Efficacy of a once-daily fixed combination halobetasol (0.01%) and tazarotene (0.045%) lotion in the treatment of localized moderate-to-severe plaque psoriasis. J Drugs Dermatol. 2019;18(3):297–299.30909352
   PubMed Web of Science ®Google Scholar
• Lebwohl MG, Sugarman JL, Gold LS, et al. Efficacy, safety, and tolerability of a halobetasol 0.01%/tazarotene 0.045% fixed combination in the treatment of severe localized plaque psoriasis: post hoc analysis of two phase III randomized controlled trials. J Drugs Dermatol. 2019;18(10):1012–1018.31584780
   PubMed Web of Science ®Google Scholar
• Lebwohl MG, Sugarman JL, Gold LS, et al. Long-term safety results from a phase 3 open-label study of a fixed combination halobetasol propionate 0.01% and tazarotene 0.045% lotion in moderate-to-severe plaque psoriasis. J Am Acad Dermatol. 2019;80(1):282–285. doi:10.1016/j.jaad.2018.09.00230227193
   PubMed Web of Science ®Google Scholar
• Bhatia ND, Pariser DM, Kircik L, et al. Safety and efficacy of a halobetasol 0.01%/tazarotene 0.045% fixed combination lotion in the treatment of moderate-to-severe plaque psoriasis: a comparison with halobetasol propionate 0.05% cream. J Clin Aesthetic Dermatol. 2018;11(11):15–19.
   PubMedGoogle Scholar
• Sugarman JL, Gold LS, Lebwohl MG, Pariser DM, Alexander BJ, Pillai R. A Phase 2, multicenter, double-blind, randomized, vehicle controlled clinical study to assess the safety and efficacy of a halobetasol/tazarotene fixed combination in the treatment of plaque psoriasis. J Drugs Dermatol. 2017;16(3):197–204.28301614
   PubMed Web of Science ®Google Scholar
• Kircik LH, Papp KA, Gold LS, Harris S, Pharm TL, Pillai R. Assessing the synergistic effect of a fixed combination halobetasol propionate 0.01% and tazarotene 0.045% lotion in moderate-to-severe plaque psoriasis. J Drugs Dermatol. 2019;18(3):279–284.30909333
   PubMed Web of Science ®Google Scholar
• Gold LS, Bagel J, Lebwohl M, Lin T, Martin G, Pillai R. Halobetasol and tazarotene: further defining the role of a unique fixed combination topical lotion in moderate-to-severe plaque psoriasis. J Drugs Dermatol. 2018;17(12):1290–1296.30586261
   PubMed Web of Science ®Google Scholar
• Gold LS, Kircik LH, Pariser D, et al. Rapid onset of action in patients with moderate-to-severe plaque psoriasis with halobetasol 0.01%/tazarotene 0.045% fixed combination. J Drugs Dermatol. 2018;17(8):863–868.30124725
   PubMed Web of Science ®Google Scholar
• Pariser DM, Green LJ, Gold LS, Sugarman JL, Lin T, Pillai R. Halobetasol 0.01%/tazarotene 0.045% lotion in the treatment of moderate-to-severe plaque psoriasis: maintenance of therapeutic effect after cessation of therapy. J Drugs Dermatol. 2018;17(7):723–726.30005093
   PubMed Web of Science ®Google Scholar
• PubChem. Tazarotene. Available from: https://pubchem.ncbi.nlm.nih.gov/compound/5381. Accessed 323, 2020.
   Google Scholar
• A safety and pharmacokinetics study of IDP-118 lotion in pediatric participants with plaque psoriasis - full text view - clinicalTrials.gov. Available from: https://clinicaltrials.gov/ct2/show/NCT03988439. Accessed 325, 2020.
   Google Scholar
• Duobrii in Combination with Biologics – Full Text View – ClinicalTrials.gov. Available from: https://clinicaltrials.gov/ct2/show/NCT04119102. Accessed 325, 2020.
   Google Scholar